In addition to increasing the curability of difficult-totreat cases, one of the current challenges is to determine the reversibility of the metabolic alterations and associated complications after viral clearance. Several contradictions have been noted Palmatine concerning HCVrelated metabolic alterations. First, most large-scale case-control studies have demonstrated that HCV infection leads to lower total cholesterol levels. In a large series, HCV-associated hypocholesterolemia was shown to be most evident with genotype 3, intermediate with genotype 1 and not significant with genotype 2. However, a proportional relationship was ever reported between TC and the viral load in G2 patients. The source of the apparent conflicts in genotype-specific hypolipidemia of CHC patients may result from individual bias which can not be eliminated completely from case-control studies. Second, the eradication of HCV was regarded to reduce the incidences of type 2 diabetes in both G1 and G2 patients. However, reduced IR after sustained virological responses was observed in G1 but not in G2 or G3 patients. Furthermore, a recent prospective study enrolled G1, 2, 3 and 4 CHC patients failed to demonstrate any difference between the mean pre- and post-anti-HCV treatment homeostasis model assessments of IR values in patients with SVR. The above inconsistencies may arise from the Germacrone heterogeneous baseline glucose metabolisms of the hosts. Given the inconclusive genotype-specific impact of HCV infection on IR, how IR affects lipid metabolism in CHC patients remains even more unclear. The most compelling findings of the current study are as follows: Although the HCV viral clearance in both G1 and G2 patients resulted in increases in most lipid profile items, posttherapeutic increases in HDL and Apo AI levels were found only in G2 patients; increased TG/HDL ratios were found only in G1 patients. Moreover, after SVR, G2 patients had lower posttreatment TG/HDL ratios and TG levels than G1 patients. Among the patients without baseline IR, G1 patients had increased post-treatment HOMA-IR levels, in contrast to G2 patients.